Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(Tos-Gly-Pro-Arg)2[R110] + H2O
2 Tos-Gly-Pro-Arg + rhodamin110
fluorogenic subtrate for thrombin
-
-
?
Abz-APGRVVGGA-Q-N-[2,4-dinitrophenyl]-ethylenediamine + H2O
?
-
-
-
?
Abz-KLRSSKQ-EDDnp + H2O
?
Abz-KLRSSQ-EDDnp + H2O
?
-
-
-
-
?
Ala-Thr-Pro-Lys-Ile-Phe-Asn + H2O
Ala-Thr-Pro-Lys + Ile-Phe-Asn
-
moderate cleavage efficiency
-
-
?
Asp-Gly-Asp-Lys-Ile-Ile-Glu + H2O
Asp-Gly-Asp-Lys + Ile-Ile-Glu
-
low cleavage efficiency
-
-
?
Asp-Thr-Arg-Ala-Ile-Gly + H2O
Asp-Thr-Arg + Ala-Ile-Gly
-
moderate cleavage efficiency
-
-
?
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Boc-Gln-Ala-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Gln-Ala-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
Boc-Gln-Arg-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Gln-Arg-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
Boc-Gln-Gly-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Gln-Gly-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
Boc-Leu-Arg-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Leu-Arg-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
Boc-Leu-GLy-Arg-7-amido-4-methylcoumarin + H2O
Boc-Leu-Gly-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Boc-Leu-Lys-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Leu-Lys-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
Boc-Phe-Ser-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Phe-Ser-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
Boc-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
Boc-Phe-Ser-Arg + 7-amino-4-methylcoumarin
-
-
-
?
Boc-Val-Leu-Lys-7-amido-4-methyl-coumarin + H2O
Boc-Val-Leu-Lys + 7-amino-4-methyl-coumarin
-
-
-
-
?
Boc-Val-Pro-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Val-Pro-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
Cbz-L-Pro-Phe-Arg-p-nitroanilide + H2O
Cbz-L-Pro-Phe-Arg + 4-nitroaniline
-
-
-
?
collagen type IV + H2O
?
-
-
-
-
?
D-Ile-Pro-Arg-p-nitroanilide + H2O
D-Ile-Pro-Arg + p-nitroaniline
-
-
-
?
defensin-1alpha + H2O
?
KLK5 is capable of processing defensin-1alpha and may be important in vaginal host defense
-
-
?
desmocollin-2 + H2O
?
-
-
-
?
desmoglein 1 + H2O
?
-
-
-
-
?
desmoglein protein 1 + H2O
?
-
-
-
?
diglutamyl-Gly-Arg-7-amido-4-methylcoumarin + H2O
diglutamyl-Gly-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
diglutamyl-Pro-Phe-Arg-7-amido-4-methylcoumarin + H2O
diglutamyl-Pro-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Fibrinogen + H2O
?
-
-
-
-
?
fibrinogen Aalpha chain + H2O
?
-
cleavage after Arg348 and Arg407
-
-
?
fibrinogen Bbeta chain + H2O
?
-
cleavage after Lys53 and Arg14
-
-
?
Fibronectin + H2O
?
-
-
-
-
?
FSR-amido-4-methylcoumarin + H2O
FSR + 7-amino-4-methylcoumarin
fluorogenic trypsin-like peptide substrate
-
-
?
Gln-Glu-Asp-Lys-Val-Leu-Gly + H2O
Gln-Glu-Asp-Lys + Val-Leu-Gly
-
low cleavage efficiency
-
-
?
Gln-Gly-Asp-Lys-Ile-Ile-Asp + H2O
Gln-Gly-Asp-Lys + Ile-Ile-Asp
-
low cleavage efficiency
-
-
?
Glu-Thr-Arg-Ile-Ile-Lys + H2O
Glu-Thr-Arg + Ile-Ile-Lys
-
moderate cleavage efficiency
-
-
?
H-Pro-Phe-Ser-Arg-7-amido-4-methyl-coumarin + H2O
H-Pro-Phe-Ser-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
high-molecular-weight kininogen + H2O
?
-
-
-
-
?
hK3 + H2O
?
-
hK5 can inactivate hK3 by subsequent cleavage after activation
-
-
?
human plasminogen + H2O
human plasmin + ?
generation of a 29 kDa fragment
-
-
?
Ile-Gln-Ser-Arg-Ile-Val-Gly + H2O
Ile-Gln-Ser-Arg + Ile-Val-Gly
-
high cleavage efficiency
-
-
?
Ile-Leu-Ser-Arg-Ile-Val
Ile-Leu-Ser-Arg + Ile-Val
-
optimal substrate sequences for KLK5
-
-
?
Ile-Leu-Ser-Arg-Ile-Val-Gly + H2O
Ile-Leu-Ser-Arg + Ile-Val-Gly
-
high cleavage efficiency
-
-
?
insulin-like growth factor-binding protein 1 + H2O
insulin-like growth factor-binding protein 1a + insulin-like growth factor-binding protein 1b
-
cleavage after Lys137
-
-
?
insulin-like growth factor-binding protein 1 + H2O
insulin-like growth factor-binding protein 4a + insulin-like growth factor-binding protein 4b
-
cleavage after Arg170
-
-
?
insulin-like growth factor-binding protein 2 + H2O
insulin-like growth factor-binding protein 2a + insulin-like growth factor-binding protein 2b
-
cleavage after Arg164
-
-
?
insulin-like growth factor-binding protein 3 + H2O
insulin-like growth factor-binding protein 3a + insulin-like growth factor-binding protein 3b + insulin-like growth factor-binding protein 3c
-
cleavage after Arg158 and Arg206
-
-
?
insulin-like growth factor-binding protein 5 + H2O
insulin-like growth factor-binding protein 5a + insulin-like growth factor-binding protein 5b + insulin-like growth factor-binding protein 5c
-
cleavage after Arg123 and Arg212
-
-
?
insulin-like growth factor-binding protein-3 + H2O
?
-
-
-
-
?
kallikrein 7 + H2O
?
-
Gln-Gly-Asp-Lys-/-Ile-Ile. KLK7 is activated at a low rate
-
-
?
kininogen + H2O
?
-
cleavage after Arg222, Arg252 and Arg374
-
-
?
L-Ile-Pro-Arg-4-nitroanilide + H2O
L-Ile-Pro-Arg + 4-nitroaniline
-
-
-
?
L-Pro-Phe-Arg-7-amido-4-methylcoumarin + H2O
L-Pro-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
N(p-tosyl)-Arg-Gly-Val 4-nitroanilide
?
-
-
-
-
?
plasminogen + H2O
?
-
cleavage after Lys77 andA rg529
-
-
?
polypeptide + H2O
peptides
pro-hK2 + H2O
hK2 + ?
-
hK5 can activate hK2 through cleavage after Lys137
-
-
?
pro-hK3 + H2O
hK3 + ?
-
hK5 can activate hK3 through cleavage after Arg85 and Lys182
-
-
?
Pro-Phe-Ser-Arg-7-amido-4-methyl-coumarin + H2O
Pro-Phe-Ser-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
pro-[stratum corneum chymotryptic enzyme] + H2O
stratum corneum chymotryptic enzyme + ?
-
stratum corneum tryptic enzyme activates stratum corneum chymotryptic enzyme through cleavage of the 31 kDa proenzyme resulting in the mature 28 kDa enzyme
-
-
?
proform filaggrin + H2O
mature filaggrin + ?
Ser-Ser-Ser-Arg-Ile-Ile-Asn + H2O
Ser-Ser-Ser-Arg + Ile-Ile-Asn
-
moderate cleavage efficiency
-
-
?
tert-butyloxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
?
tert-butyloxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-Phe-Ser-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
tert-butyloxycarbonyl-Val-Pro-Arg-7-amido-4-methylcoumarin + H2O
?
Tos-Gly-Pro-Arg-7-amido-4-methyl-coumarin + H2O
Tos-Gly-Pro-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
Tos-Gly-Pro-Lys-7-amido-4-methylcoumarin + H2O
Tos-Gly-Pro-Lys + 7-amino-4-methylcoumarin
-
-
-
?
tosyl-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
tosyl-Gly-Pro-Arg + 7-amino-4-methylcoumarin
-
-
-
?
Vitronectin + H2O
?
-
cleavage after Arg8
-
-
?
VPR-amido-4-methylcoumarin + H2O
VPR + 7-amino-4-methylcoumarin
fluorogenic trypsin-like peptide substrate
-
-
?
Z-Gly-Gly-Arg-7-amido-4-methyl-coumarin + H2O
Z-Gly-Gly-Arg + 7-amino-4-methyl-coumarin
-
-
-
-
?
additional information
?
-
Abz-KLRSSKQ-EDDnp + H2O
?
-
-
-
-
?
Abz-KLRSSKQ-EDDnp + H2O
?
-
-
-
?
desmocollin-3 + H2O
?
-
-
-
-
?
desmocollin-3 + H2O
?
-
-
-
?
Gelatin + H2O
?
-
-
-
-
?
Gelatin + H2O
?
-
-
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
-
-
?
polypeptide + H2O
peptides
enzyme is regulated by binding to protease inhibitors
-
?
proform filaggrin + H2O
mature filaggrin + ?
the enzyme and profilaggrin co-localize in the stratum granulosum in human epidermis. The enzyme interacts with its substrates in granular cells
-
-
?
proform filaggrin + H2O
mature filaggrin + ?
the filaggrin linker domain is the site for processing, recombinant human 53-kDa filaggrin protein
41-kDa filaggrin fragment
-
?
tert-butyloxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
?
-
best substrate
-
-
?
tert-butyloxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
?
best substrate
-
-
?
tert-butyloxycarbonyl-Val-Pro-Arg-7-amido-4-methylcoumarin + H2O
?
-
best substrate
-
-
?
tert-butyloxycarbonyl-Val-Pro-Arg-7-amido-4-methylcoumarin + H2O
?
best substrate
-
-
?
additional information
?
-
no activity with AAPF-amido-4-methylcoumarin
-
-
?
additional information
?
-
-
no activity with AAPF-amido-4-methylcoumarin
-
-
?
additional information
?
-
enzyme shows trypsin-like but not chymotrypsin-like activity
-
-
?
additional information
?
-
-
enzyme shows trypsin-like but not chymotrypsin-like activity
-
-
?
additional information
?
-
involved in ovarian cancer
-
-
?
additional information
?
-
regulation by steroid homones
-
-
?
additional information
?
-
the enzyme is differentially expressed at the mRNA and protein level in diverse malignancies including cancer
-
-
?
additional information
?
-
-
the enzyme is differentially expressed at the mRNA and protein level in diverse malignancies including cancer
-
-
?
additional information
?
-
-
KLK5 plays a central role in skin desquamation as an initiating activating enzyme in proteolytic cascades formed by kallikreins
-
-
?
additional information
?
-
displays a trypsin-like specificity with strong preference for Arg at position P1. The S1 pocket of hK5 is very specific for P1-Arg side chains. Thr, Asn, Gln, and Ile are tolerated at position P1, whereas the residual amino acids, in particular with large aromatic side chains and Lys, are hardly accepted. Ser is slightly preferred over Asn, Thr, and Ala at position P2, whereas among all other residues only Arg and Tyr are rejected. Most amino acids, in particular Met, Phe, and Tyr but not Asp, are accepted in position P3. An unusual preference for Gly followed by Tyr, Val, and Pro is observed at position P4
-
-
?
additional information
?
-
-
KLK5 activates itself efficiently at the cleavage site Ser-Ser-Ser-Arg-/-Ile-Ile. KLK5 is able to induce signaling events via proteinase-activated receptor-2. Strong preference for P1-Arg over Lys (Lys is accepted by the S1 pocket to some extent) and the complete exclusion of chymotrypsin-specific substrates with a Phe or Tyr side chain in P1 position. Preference for Ala and Lys at P2, preference for Gly in P4
-
-
?
additional information
?
-
-
no activity with Abz-KLYSSKQ-EDDnp
-
-
?
additional information
?
-
no activity with peptides CPGRVVGGC, and QVEPKKCPGRVVGGCVAHPHS
-
-
?
additional information
?
-
-
no activity with tert-butyloxycarbonyl-Val-Leu-Lys-7-amido-4-methylcoumarin, tert-butyloxycarbonyl-Glu-Lys-Lys-7-amido-4-methylcoumarin, acetyl-Ile-Glu-Thr-Asp-7-amido-4-methylcoumarin, succinyl-Ala-Ala-Pro-Phe-7-amido-4-methylcoumarin, succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin, casein, laminin, and single-chain tissue-type plasminogen activator
-
-
?
additional information
?
-
unregulated KLK5 directly activates proteinase-activated receptor 2 and induces nuclear factor kappaB-mediated overexpression of TSLP, intercellular adhesion molecule 1, tumor necrosis factor alpha, and IL8
-
-
?
additional information
?
-
-
unregulated KLK5 directly activates proteinase-activated receptor 2 and induces nuclear factor kappaB-mediated overexpression of TSLP, intercellular adhesion molecule 1, tumor necrosis factor alpha, and IL8
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(S)-methyl-1-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanoyl) pyrrolidine-2-carboxylate
-
(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-methylbutanoate
-
(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-phenylpropanoate
-
8,8'-paepalantine dimer
-
potent competitive inhibitor
alpha2-antiplasmin
-
50% inhibition at 0.8 microM in 0.6 min
-
antipain
-
13% inhibition at 0.2 mM
antithrombin III
-
50% inhibition at 0.8 microM in 6 min
-
Aprotinin
-
34% inhibition at 0.1 g/ml
diisopropylfluorophosphate
-
87% inhibition at 2 mM
E-64
-
12% inhibition at 0.5 mM
fukugetin
-
mixed-type inhibitor
lympho-epithelial Kazal type inhibitor fragment D5
-
-
lympho-epithelial Kazal type inhibitor fragment D6
-
-
lympho-epithelial Kazal type inhibitor fragment D8-D11
-
-
lympho-epithelial Kazal type inhibitor fragment D9-D15
-
-
lymphoepithelial Kazal-type 5 serine protease inhibitor
-
-
-
N-(4-carbamimidoyl-2-fluorophenyl)-2-hydroxybenzamide
pIC50: 5.6, compared to pIC50 for KLK1: 5.5
N-(4-carbamimidoyl-2-methylphenyl)-2-hydroxybenzamide
pIC50: 4.9, compared to pIC50 for KLK1: 5.3
N-(4-carbamimidoyl-3-chlorophenyl)-2-hydroxy-3-methoxybenzamide
pIC50: 5.0, compared to pIC50 for KLK1: 5.9
N-(4-carbamimidoyl-3-fluorophenyl)-2-hydroxy-3-methoxybenzamide
pIC50: 6.0, compared to pIC50 for KLK1: 6.6
N-(4-carbamimidoyl-3-fluorophenyl)-2-hydroxybenzamide
pIC50: 4.7, compared to pIC50 for KLK1: 4.9
N-(4-carbamimidoylphenyl)-1-methyl-1H-benzimidazole-2-carboxamide
PIC50: 3.7, compared to pIC50 for KLK1: 3.7
N-(4-carbamimidoylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
pIC50: 3.3, compared to pIC50 for KLK1: 3.3
N-(4-carbamimidoylphenyl)-2,3-dihydroxybenzamide
pIC50: 5.6, compared to pIC50 for KLK1: 5.4
N-(4-carbamimidoylphenyl)-2-hydroxy-3-methoxybenzamide
pIC50: 6.3, compared to pIC50 for KLK1: 6.5
N-(4-carbamimidoylphenyl)-2-hydroxy-3-methylbenzamide
pIC50: 5.1, compared to pIC50 for KLK1: 5.5
N-(4-carbamimidoylphenyl)-2-hydroxybenzamide
PIC50: 5.2, compared to pIC50 for KLK1: 4.9
N-(4-carbamimidoylphenyl)-2-oxopiperidine-3-carboxamide
pIC50: 3.3, compared to pIC50 for KLK1: 3.3
N-(4-carbamimidoylphenyl)-2-oxotetrahydropyrimidine-1(2H)-carboxamide
pIC50: 3.2, compared to pIC50 for KLK1: 3.2
N-(4-carbamimidoylphenyl)-3-chloro-2-hydroxybenzamide
pIC50: 5.6, compared to pIC50 for KLK1: 6.2
N-(4-carbamimidoylphenyl)-3-ethoxy-2-hydroxybenzamide
pIC50: 5.3, compared to pIC50 for KLK1: 6.9
N-alpha-p-tosyl-L-leucine-chloromethylketone
-
14% inhibition at 0.2 mM
N-alpha-p-tosyl-L-phenylalanine-chloromethylketone
-
14% inhibition at 0.2 mM
o-phenanthroline
-
10% inhibition at 2 mM
vioxanthin
-
potent competitive inhibitor
leupeptin
-
leupeptin
-
70% inhibition at 0.1 mM
SPINK9
-
i.e. serine protease inhibitor Kazal type 9, KLK5-specific inhibitor, KLK5 degradation of fibrinogen was totally inhibited by SPINK9
-
SPINK9
-
i.e. LEKTI-2. Inhibits KLK5 but not KLK7, 14 or other serine proteases tested including trypsin, plasmin and thrombin. LEKTI-2 contributes to the regulation of the desquamation process in human skin by specifically inhibiting KLK5
-
Zn2+
-
75% inhibition at 12 nM, 93.5% inhibition at 60 nM, 97.5% inhibition at 120 nM, complete inhibition at 1200 nM
Zn2+
non-competitive inhibition, the enzyme activity is restored by addition of EDTA showing reversibility
additional information
not inhibited by lympho-epithelial Kazal type inhibitor fragment D1
-
additional information
no significant effect on enzyme activity by chondroitin
-
additional information
identification and design of KLK5 inhibitors with encouraging potency and efficiency, with 10-100fold selectivity over the key liability target KLK1
-
additional information
-
not inhibited by soybean trypsin inhibitor, benzamidine, pepstatin, EDTA, and chymostatin
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Clinical significance of kallikrein 5 as a novel prognostic biomarker in gastric adenocarcinoma.
Adenocarcinoma of Lung
PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.
Breast Neoplasms
Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.
Breast Neoplasms
Evaluation of Kallikrein-related Peptidase 5 Expression and its Significance for Breast Cancer Patients: Association with Kallikrein-related Peptidase 7 Expression.
Breast Neoplasms
Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer.
Breast Neoplasms
Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model.
Breast Neoplasms
The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation.
Carcinogenesis
Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis.
Carcinoma
Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.
Carcinoma
Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis.
Carcinoma
Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma.
Carcinoma
Kallikrein-related Peptidase 5 (KLK5) Expression and Distribution in Canine Cutaneous Squamous Cell Carcinoma.
Carcinoma
The Co-Expression of Kallikrein 5 and Kallikrein 7 Associates with Poor Survival in Non-HPV Oral Squamous-Cell Carcinoma.
Carcinoma, Squamous Cell
Kallikrein-related Peptidase 5 (KLK5) Expression and Distribution in Canine Cutaneous Squamous Cell Carcinoma.
Chronic Urticaria
Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
Colitis
Glutathione peroxidase 2 and aquaporin 8 as new markers for colonic inflammation in experimental colitis and inflammatory bowel diseases: an important role for H2O2?
Dandruff
Exacerbated dandruff in the absence of kallikrein-related peptidase 5 protease.
Dermatitis
Increase in pruritogenic kallikrein 5 in the skin of NC mice with chronic dermatitis.
Dermatitis
Skin pH Is the Master Switch of Kallikrein 5-Mediated Skin Barrier Destruction in a Murine Atopic Dermatitis Model.
Eczema
Transcriptional gene silencing of kallikrein 5 and kallikrein 7 using siRNA prevents epithelial cell detachment induced by alkaline shock in an in vitro model of eczema.
Eosinophilic Esophagitis
Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis.
Influenza, Human
Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.
Influenza, Human
Kallikrein-related peptidase 5 and seasonal influenza viruses, limitations of the experimental models for activating proteases.
Influenza, Human
Kallikrein-Related Peptidase 5 Contributes to H3N2 Influenza Virus Infection in Human Lungs.
Mycosis Fungoides
Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression.
Neoplasms
Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.
Neoplasms
Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression.
Neoplasms
Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7.
Neoplasms
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Neoplasms
Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
Neoplasms
Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors.
Neoplasms
Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.
Neoplasms
Kallikrein 5 overexpression is associated with poor prognosis in uterine cervical cancer.
Neoplasms
Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer.
Neoplasms
Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies.
Neoplasms
PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.
Neoplasms
Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker.
Neoplasms
Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5.
Neoplasms
The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway.
Netherton Syndrome
A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
Netherton Syndrome
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.
Netherton Syndrome
Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.
Netherton Syndrome
Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
Netherton Syndrome
Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.
Netherton Syndrome
Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
Netherton Syndrome
Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.
Netherton Syndrome
SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Netherton Syndrome
Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.
Netherton Syndrome
Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
Ovarian Neoplasms
Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.
Ovarian Neoplasms
Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
Ovarian Neoplasms
Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.
Ovarian Neoplasms
Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.
Ovarian Neoplasms
Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
Ovarian Neoplasms
The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids.
Prostatic Neoplasms
Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer.
Prostatic Neoplasms
Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression.
Pruritus
Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
Pruritus
Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression.
Psoriasis
Expression of bleomycin hydrolase in keratinization disorders.
Rosacea
A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.
Rosacea
Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.
Rosacea
Citron Essential Oils Alleviate the Mediators Related to Rosacea Pathophysiology in Epidermal Keratinocytes.
Rosacea
Coptis chinensis Franch Directly Inhibits Proteolytic Activation of Kallikrein 5 and Cathelicidin Associated with Rosacea in Epidermal Keratinocytes.
Rosacea
Doxycycline Indirectly Inhibits Proteolytic Activation of Tryptic Kallikrein-Related Peptidases and Activation of Cathelicidin.
Rosacea
Endoplasmic reticulum stress: key promoter of rosacea pathogenesis.
Rosacea
Hyaluronan Oligosaccharides Improve Rosacea-Like Phenotype through Anti-Inflammatory and Epidermal Barrier-Improving Effects.
Rosacea
Kallikrein 5-Mediated Inflammation in Rosacea: Clinically Relevant Correlations with Acute and Chronic Manifestations in Rosacea and How Individual Treatments May Provide Therapeutic Benefit.
Rosacea
Multifunctional Serine Protease Inhibitor-Coated Water-Soluble Gold Nanoparticles as a Novel Targeted Approach for the Treatment of Inflammatory Skin Diseases.
Rosacea
TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes.
Skin Diseases
Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
Skin Diseases
Expression of bleomycin hydrolase in keratinization disorders.
Skin Diseases
Hyaluronan Oligosaccharides Improve Rosacea-Like Phenotype through Anti-Inflammatory and Epidermal Barrier-Improving Effects.
Skin Diseases
Multifunctional Serine Protease Inhibitor-Coated Water-Soluble Gold Nanoparticles as a Novel Targeted Approach for the Treatment of Inflammatory Skin Diseases.
Skin Diseases
Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses.
Sleep Deprivation
Sleep loss and cytokines levels in an experimental model of psoriasis.
Squamous Cell Carcinoma of Head and Neck
Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis.
Squamous Cell Carcinoma of Head and Neck
Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma.
Triple Negative Breast Neoplasms
Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer: tissue expression analysis and relationship with disease course.
Ureteral Obstruction
MiR-382 targeting of kallikrein 5 contributes to renal inner medullary interstitial fibrosis.
Urticaria
Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
Uterine Cervical Neoplasms
Kallikrein 5 overexpression is associated with poor prognosis in uterine cervical cancer.
Virus Diseases
Kallikrein-Related Peptidase 5 Contributes to H3N2 Influenza Virus Infection in Human Lungs.
Vulvodynia
Decreased concentration of protease inhibitors: possible contributors to allodynia and hyperalgesia in women with vestibulodynia.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.004
Abz-KLRSSKQ-EDDnp
-
pH and temperature not specified in the publication
0.05
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.13
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.11
benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.61
Boc-Gln-Ala-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
1.41
Boc-Gln-Arg-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.57
Boc-Gln-Gly-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.48
Boc-Leu-Arg-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.15
Boc-Leu-GLy-Arg-7-amido-4-methylcoumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
1.01
Boc-Leu-Lys-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.19
Boc-Phe-Ser-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.64
Boc-Val-Leu-Lys-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.02
Boc-Val-Pro-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.03
diglutamyl-Gly-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.03
diglutamyl-Pro-Phe-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
1.77
H-Pro-Phe-Ser-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.6
L-Ile-Pro-Arg-p-nitroanilide
1.69
Tos-Gly-Pro-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.31
Z-Gly-Gly-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.6
L-Ile-Pro-Arg-p-nitroanilide
in 0.1 M Tris, 0.5 M NaCl, pH 8
0.6
L-Ile-Pro-Arg-p-nitroanilide
L-Ile-Pro-Arg-4-nitroanilide
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Boeckmann, B.; Bairoch, A.; Apweiler, R.; Blatter, M.C.; Estreicher, A.; Gasteiger, E.; Martin M.J.; Michoud, K.; O'Donovan, C.; Phan, I.; Pilbout, S.; Schneider, M.
The SWISS-PROT protein knowledgebase and its supplement TrEMBL
Nucleic Acids Res.
31
365-370
2003
Mus musculus (P15945), Homo sapiens (Q9Y337)
brenda
Yousef, G.M.; Diamandis, E.P.
The new human tissue kallikrein gene family: structure, function, and association to disease
Endocr. Rev.
22
184-204
2001
Homo sapiens (Q9Y337)
brenda
Brattsand, M.; Egelrud, T.
Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation
J. Biol. Chem.
274
30033-30040
1999
Homo sapiens (Q9Y337), Homo sapiens
brenda
Ekholm, I.E.; Brattsand, M.; Egelrud, T.
Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process?
J. Invest. Dermatol.
114
56-63
2000
Homo sapiens (Q9Y337), Homo sapiens
brenda
Yousef, G.M.; Kapadia, C.; Polymeris, M.E.; Borgono, C.; Hutchinson, S.; Wasney, G.A.; Soosaipillai, A.; Diamandis, E.P.
The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids
Biochim. Biophys. Acta
1628
88-96
2003
Homo sapiens (Q9Y337), Homo sapiens
brenda
Prezas, P.; Arlt, M.J.; Viktorov, P.; Soosaipillai, A.; Holzscheiter, L.; Schmitt, M.; Talieri, M.; Diamandis, E.P.; Krueger, A.; Magdolen, V.
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells
Biol. Chem.
387
807-811
2006
Homo sapiens
brenda
Caubet, C.; Jonca, N.; Brattsand, M.; Guerrin, M.; Bernard, D.; Schmidt, R.; Egelrud, T.; Simon, M.; Serre, G.
Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7
J. Invest. Dermatol.
122
1235-1244
2004
Homo sapiens
brenda
Michael, I.P.; Sotiropoulou, G.; Pampalakis, G.; Magklara, A.; Ghosh, M.; Wasney, G.; Diamandis, E.P.
Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression
J. Biol. Chem.
280
14628-14635
2005
Homo sapiens
brenda
Michael, I.P.; Pampalakis, G.; Mikolajczyk, S.D.; Malm, J.; Sotiropoulou, G.; Diamandis, E.P.
Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression
J. Biol. Chem.
281
12743-12750
2006
Homo sapiens
brenda
Komatsu, N.; Tsai, B.; Sidiropoulos, M.; Saijoh, K.; Levesque, M.A.; Takehara, K.; Diamandis, E.P.
Quantification of eight tissue kallikreins in the Stratum corneum and sweat
J. Invest. Dermatol.
126
925-929
2006
Homo sapiens
brenda
Kurlender, L.; Yousef, G.M.; Memari, N.; Robb, J.D.; Michael, I.P.; Borgono, C.; Katsaros, D.; Stephan, C.; Jung, K.; Diamandis, E.P.
Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer
Tumour Biol.
25
149-156
2004
Homo sapiens
brenda
Yousef, G.M.; White, N.M.; Kurlender, L.; Michael, I.; Memari, N.; Robb, J.D.; Katsaros, D.; Stephan, C.; Jung, K.; Diamandis, E.P.
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer
Tumour Biol.
25
221-227
2005
Homo sapiens
brenda
Petraki, C.D.; Gregorakis, A.K.; Vaslamatzis, M.M.; Papanastasiou, P.A.; Yousef, G.M.; Levesque, M.A.; Diamandis, E.P.
Prognostic Implications of the Immunohistochemical Expression of Human Kallikreins 5, 6, 10 and 11 in Renal Cell Carcinoma
Tumour Biol.
27
1-7
2006
Homo sapiens
brenda
Shinoda, Y.; Kozaki, K.; Imoto, I.; Obara, W.; Tsuda, H.; Mizutani, Y.; Shuin, T.; Fujioka, T.; Miki, T.; Inazawa, J.
Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells
Cancer Sci.
98
1078-1086
2007
Homo sapiens
brenda
Voegeli, R.; Rawlings, A.V.; Doppler, S.; Heiland, J.; Schreier, T.
Profiling of serine protease activities in human stratum corneum and detection of a stratum corneum tryptase-like enzyme
Int. J. Cosmet. Sci.
29
191-200
2007
Homo sapiens
brenda
Debela, M.; Magdolen, V.; Schechter, N.; Valachova, M.; Lottspeich, F.; Craik, C.S.; Choe, Y.; Bode, W.; Goettig, P.
Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences
J. Biol. Chem.
281
25678-25688
2006
Homo sapiens (Q9Y337)
brenda
Debela, M.; Goettig, P.; Magdolen, V.; Huber, R.; Schechter, N.M.; Bode, W.
Structural basis of the zinc inhibition of human tissue kallikrein 5
J. Mol. Biol.
373
1017-1031
2007
Homo sapiens (Q9Y337), Homo sapiens
brenda
Deraison, C.; Bonnart, C.; Lopez, F.; Besson, C.; Robinson, R.; Jayakumar, A.; Wagberg, F.; Brattsand, M.; Hachem, J.P.; Leonardsson, G.; Hovnanian, A.
LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction
Mol. Biol. Cell
18
3607-3619
2007
Homo sapiens (Q9Y337)
brenda
Rajapakse, S.; Ogiwara, K.; Yamano, N.; Kimura, A.; Hirata, K.; Takahashi, S.; Takahashi, T.
Characterization of mouse tissue kallikrein 5
Zool. Sci.
23
963-968
2006
Mus musculus
brenda
Shaw, J.L.; Petraki, C.; Watson, C.; Bocking, A.; Diamandis, E.P.
Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense
Biol. Chem.
389
1513-1522
2008
Homo sapiens (Q9Y337)
brenda
Debela, M.; Beaufort, N.; Magdolen, V.; Schechter, N.M.; Craik, C.S.; Schmitt, M.; Bode, W.; Goettig, P.
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7
Biol. Chem.
389
623-632
2008
Homo sapiens
brenda
Korbakis, D.; Gregorakis, A.K.; Scorilas, A.
Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker
Clin. Chem.
55
904-913
2009
Homo sapiens (Q9Y337), Homo sapiens
brenda
Pettus, J.R.; Johnson, J.J.; Shi, Z.; Davis, J.W.; Koblinski, J.; Ghosh, S.; Liu, Y.; Ravosa, M.J.; Frazier, S.; Stack, M.S.
Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity
Histol. Histopathol.
24
197-207
2009
Homo sapiens
brenda
Brattsand, M.; Stefansson, K.; Hubiche, T.; Nilsson, S.K.; Egelrud, T.
SPINK9: A selective, skin-specific Kazal-type serine protease inhibitor
J. Invest. Dermatol.
129
1656-1665
2009
Homo sapiens
brenda
Meyer-Hoffert, U.; Wu, Z.; Schroeder, J.M.
Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor
PLoS ONE
4
e4372
2009
Homo sapiens
brenda
Mavridis, K.; Talieri, M.; Scorilas, A.
KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone
Biol. Chem.
391
467-474
2010
Homo sapiens (Q9Y337)
brenda
Li, X.; Liu, J.; Wang, Y.; Zhang, L.; Ning, L.; Feng, Y.
Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies
Cancer Sci.
100
601-607
2009
Homo sapiens
brenda
Briot, A.; Deraison, C.; Lacroix, M.; Bonnart, C.; Robin, A.; Besson, C.; Dubus, P.; Hovnanian, A.
Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome
J. Exp. Med.
206
1135-1147
2009
Mus musculus (Q9D140), Mus musculus
brenda
Teixeira, T.S.; Freitas, R.F.; Abrahao, O.; Devienne, K.F.; de Souza, L.R.; Blaber, S.I.; Blaber, M.; Kondo, M.Y.; Juliano, M.A.; Juliano, L.; Puzer, L.
Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7
Bioorg. Med. Chem. Lett.
21
6112-6115
2011
Homo sapiens
brenda
Britland, S.; Hoyle, M.
Transcriptional gene silencing of kallikrein 5 and kallikrein 7 using siRNA prevents epithelial cell detachment induced by alkaline shock in an in vitro model of eczema
Biotechnol. Prog.
28
485-489
2011
Homo sapiens
brenda
Jiang, R.; Shi, Z.; Johnson, J.J.; Liu, Y.; Stack, M.S.
Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma
J. Biol. Chem.
286
9127-9135
2011
Homo sapiens
brenda
De Souza, L.; M. Melo, P.; Paschoalin, T.; Carmona, A.; Kondo, M.; Hirata, I.; Blaber, M.; Tersariol, I.; Takatsuka, J.; Juliano, M.; Juliano, L.; Gomes, R.; Puzer, L.
Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin
Biochem. Biophys. Res. Commun.
433
333-337
2013
Homo sapiens (Q9Y337)
brenda
Sakabe, J.; Yamamoto, M.; Hirakawa, S.; Motoyama, A.; Ohta, I.; Tatsuno, K.; Ito, T.; Kabashima, K.; Hibino, T.; Tokura, Y.
Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes
J. Biol. Chem.
288
17179-17189
2013
Homo sapiens (Q9Y337), Homo sapiens
brenda
Santos, J.A.; Kondo, M.Y.; Freitas, R.F.; dos Santos, M.H.; Ramalho, T.C.; Assis, D.M.; Juliano, L.; Juliano, M.A.; Puzer, L.
The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins
Bioorg. Med. Chem. Lett.
26
1485-1489
2016
Homo sapiens
brenda
White, G.V.; Edgar, E.V.; Holmes, D.S.; Lewell, X.Q.; Liddle, J.; Polyakova, O.; Smith, K.J.; Thorpe, J.H.; Walker, A.L.; Wang, Y.; Young, R.J.; Hovnanian, A.
Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome
Bioorg. Med. Chem. Lett.
29
821-825
2019
Homo sapiens (Q9Y337)
brenda
Hoelz, L.V.B.; Zorzanelli, B.C.; Azevedo, P.H.R.A.; Passos, S.G.; de Souza, L.R.; Zani, M.; Pinheiro, S.; Puzer, L.; Dias, L.R.S.; Muri, E.M.F.
Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5
Eur. J. Med. Chem.
112
39-47
2016
Homo sapiens (Q9Y337), Homo sapiens
brenda
Andoh, T.; Tsujii, K.; Kuraishi, Y.
Increase in pruritogenic kallikrein 5 in the skin of NC mice with chronic dermatitis
Exp. Dermatol.
24
978-980
2015
Mus musculus (P15945)
brenda
Yang, F.; Li, J.Y.; Yin, Q.N.; Yang, K.; Dong, S.N.; Bai, L.J.; Liu, P.; Tong, X.W.
Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer tissue expression analysis and relationship with disease course
Genet. Mol. Res.
14
9655-9666
2015
Homo sapiens (Q9Y337), Homo sapiens
brenda
Cartner, T.; Brand, N.; Tian, K.; Saud, A.; Carr, T.; Stapleton, P.; Lane, M.E.; Rawlings, A.V.
Effect of different alcohols on stratum corneum kallikrein 5 and phospholipase A2 together with epidermal keratinocytes and skin irritation
Int. J. Cosmet. Sci.
39
188-196
2017
Homo sapiens (Q9Y337)
brenda
Jang, H.; Matsuda, A.; Jung, K.; Karasawa, K.; Matsuda, K.; Oida, K.; Ishizaka, S.; Ahn, G.; Amagai, Y.; Moon, C.; Kim, S.H.; Arkwright, P.D.; Takamori, K.; Matsuda, H.; Tanaka, A.
Skin pH is the master switch of kallikrein 5-mediated skin barrier destruction in a murine atopic dermatitis model
J. Invest. Dermatol.
136
127-135
2016
Mus musculus (P15945), Mus musculus
brenda